News

The ICORG 08-02 Nilotinib study has reached its target accrual of 60 patients in May 2011. The last 8 patients were accrued within 8 weeks, just making the mid-May deadline. As a result of this great study teamwork and effort we are able to report on the primary objective for all 60 patients. Upon study completion an abstract has been recently submitted to a top U.S. meeting (American Society of Hematology (ASH)) and we are hopeful that it will be accepted as an oral presentation at the next ASH meeting in December 2011.

… Read more

Information Day

Post-Graduate Opportunities in Translational Cancer Research
Date: Friday December 17th 2010
Time: 11:00 – 17:00
Venue: Trinity College Dublin

ICORG would like to highlight an abstract relating to an ICORG in-house study, The PAD (Ireland) Study for Patients with Refractory and Relapsed Myeloma (ICORG 05-01) which was presented at the 12th International Myeloma Workshop, which took place in Washington, USA, from 26th February to 1st March 2009.

Myriam is a scientist with an oncology clinical trials background who has worked as a coordinator at the Institute Claudius Regaud, Toulouse, France. This is a highly regarded cancer centre which is a big centre in an ICORG like network in France.

New ICORG Vice-Chair Dr Ray McDermott, Consultant Medical Oncologist, AMNCH; ICORG/ECOG PI, has recently been elected unopposed as the new Vice Chair of ICORG. He began his four year term of office on 1st January 2009.

ICORG’s new Chair Dr Paul Browne, Consultant Haematologist, St James’s Hospital, took up his four year term of office on 1st January 2009.

We would like to welcome ICORG’s new Chair, Dr Paul Browne, Consultant Haematologist, St James’s Hospital, who takes up his four year term of office on 1st January 2009.

The ICORG Pharmacovigilance Unit has recently expanded and is pleased to welcome Armelle Donohoe, PhV Consultant and Sandra Boldrin, PhV Associate.

Armelle has over ten years experience in pharmacovigilance, and Sandra has worked in the area for two years.

Sandra is now the third ICORG employee to successfully complete the EMEA’s EudraVigilance training programme.

For more information on the ICORG group structure click here

Update on availability of the experimental drug abiraterone for treatment of prostate cancer in Ireland

On July 22nd 2008, exciting positive Phase 1 results were published for a new drug abiraterone acetate (Cougar Biotechnology Inc.®)in prostate cancer patients with advanced disease.